Standard BioTools Inc (NASDAQ:LAB)’s traded shares stood at 0.87 million during the last session, with the company’s beta value hitting 1.57. At the close of trading, the stock’s price was $1.82, to imply an increase of 3.41% or $0.06 in intraday trading. The LAB share’s 52-week high remains $3.04, putting it -67.03% down since that peak but still an impressive 33.52% since price per share fell to its 52-week low of $1.21. The company has a valuation of $677.52M, with an average of 1.53 million shares in intraday trading volume over the past 10 days and average of 1.82 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Standard BioTools Inc (LAB), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give LAB a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.03.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Standard BioTools Inc (NASDAQ:LAB) trade information
After registering a 3.41% upside in the last session, Standard BioTools Inc (LAB) has traded red over the past five days. The 5-day price performance for the stock is -1.09%, and -19.47% over 30 days. With these gigs, the year-to-date price performance is -17.65%. Short interest in Standard BioTools Inc (NASDAQ:LAB) saw shorts transact 14.68 million shares and set a 6.5 days time to cover.
The extremes give us $3.25 and $3.25 for target low and target high price respectively. As such, LAB has been trading -78.57% off suggested target high and -78.57% from its likely low.
Standard BioTools Inc (LAB) estimates and forecasts
Looking at statistics comparing Standard BioTools Inc share performance against respective industry, we note that the company has outperformed competitors. Standard BioTools Inc (LAB) shares are -21.55% down over the last 6 months, with its year-to-date growth rate higher than industry average at 53.66% against 24.50%. The rating firms project that company’s revenue will grow 60.99% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 43.03M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 45.6M.Earnings reports from the last fiscal year show that sales brought in 28.19M and 45.54M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 52.67% before jumping 0.13% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 8.72% for the past 5-year period. While 2024 is set for a 62.06% return in earnings, projections for the next 5 years are at -8.06% annually.
LAB Dividends
Standard BioTools Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
Standard BioTools Inc insiders hold 1.93% of total outstanding shares, with institutional holders owning 73.33% of the shares at 74.78% float percentage. In total, 73.33% institutions holds shares in the company, led by CASDIN CAPITAL, LLC. As of 2024-06-30, the company held over 63.96 million shares (or 17.1782% of shares), all amounting to roughly $113.21 million.
The next major institution holding the largest number of shares is VIKING GLOBAL INVESTORS LP with 58.65 million shares, or about 15.7524% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $103.81 million.
